Mereo BioPharma Group plc (MREO) is a pre-revenue clinical-stage rare disease biopharmaceutical company with no approved products and no product sales revenue as of March 31, 2026. The MFFAIS-computed liquidation values (CLV, LLV, OLV) all stand at $36.7 million as of the current period, reflecting what is effectively a near-cash-only asset base under liquidation conditions. The balance sheet is dominated by cash and cash equivalents, which management states will extend operations into mid-2027 under current burn rates. Net cash used in operating activities for Q1 2026 was $4.3 million, a material improvement from $8.3 million in Q1 2025, driven by lower G&A costs and receipt of $1.9 million ADR program reimbursement. The accumulated deficit stands at $507.5 million as of March 31, 2026. Under a liquidation lens, the asset side of the balance sheet is almost entirely composed of cash (100% recovery) and minimal other liquid items; all intangible assets (drug IP, licenses from Novartis and AstraZeneca, in-process R&D) receive a zero haircut under the lens as they have no stand-alone liquidation value absent an operating buyer. The liability stack carries no significant interest-bearing debt following the February 2025 conversion of convertible loan notes. However, several contingent and off-balance-sheet obligations are material: (1) the Novartis APA includes a provision requiring payment of a percentage of asset sale proceeds on any liquidating transaction, directly reducing recoverable proceeds in a wind-up; (2) the Amended AstraZeneca License Agreement carries up to $114.3 million in contingent milestone obligations, though these are conditioned on development/regulatory success and are currently ascribed nil fair value; (3) the Ultragenyx manufacturing and supply agreement generated a $2.3 million charge in Q1 2026 for cancellation of manufacturing slots, with additional contingent cancellation costs not yet estimable. A putative securities class action (Dodge v. Mereo, filed February 4, 2026) is pending in SDNY with no reserve established; the quantum of potential damages is unestimated and could represent a material unrecorded liability in a liquidation scenario. The filing does not separately XBRL-tag cash and cash equivalents, intangible assets, or total liabilities as discrete line items in the TAG_CONTEXT provided, so precise balance sheet line values are not available from XBRL for this period. The disclosed TAG_CONTEXT is empty, precluding any tag-level analysis. All material balance-sheet observations must therefore be sourced from the filing narrative and financial statement tables embedded in the HTML. The recovery posture is thin positive or potentially negative depending on the resolution of the Novartis asset-transfer payment obligation and the securities class action.
▼ Community Notes